547 related articles for article (PubMed ID: 16775173)
21. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
23. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population.
FitzGerald LM; Thomson R; Polanowski A; Patterson B; McKay JD; Stankovich J; Dickinson JL
Prostate; 2008 Sep; 68(13):1373-9. PubMed ID: 18537123
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
25. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels.
Jesser C; Mucci L; Farmer D; Moon C; Li H; Gaziano JM; Stampfer M; Ma J; Kantoff P
Br J Cancer; 2008 Nov; 99(10):1743-7. PubMed ID: 18827812
[TBL] [Abstract][Full Text] [Related]
26. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.
Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
28. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness.
Cicek MS; Nock NL; Li L; Conti DV; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1331-6. PubMed ID: 15298954
[TBL] [Abstract][Full Text] [Related]
29. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
Nam RK; Zhang WW; Trachtenberg J; Diamandis E; Toi A; Emami M; Ho M; Sweet J; Evans A; Jewett MA; Narod SA
J Clin Oncol; 2003 Jun; 21(12):2312-9. PubMed ID: 12805332
[TBL] [Abstract][Full Text] [Related]
30. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.
Kalay E; Ergen A; Narter F; Agaçhan B; Görmüs U; Yigit N; Isbir T
Anticancer Res; 2009 Apr; 29(4):1395-8. PubMed ID: 19414393
[TBL] [Abstract][Full Text] [Related]
31. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
Park K; Kim JH; Jeon HG; Byun SS; Lee E
Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
33. Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
Sävblom C; Giwercman A; Malm J; Halldén C; Lundin K; Lilja H; Giwercman Y
Int J Androl; 2009 Oct; 32(5):479-85. PubMed ID: 18336535
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
[TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
Platz EA; Rohrmann S; Pearson JD; Corrada MM; Watson DJ; De Marzo AM; Landis PK; Metter EJ; Carter HB
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):390-6. PubMed ID: 15734963
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
38. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
[TBL] [Abstract][Full Text] [Related]
39. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
[TBL] [Abstract][Full Text] [Related]
40. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
